HC Wainwright & Co. Maintains Buy on ADC Therapeutics, Raises Price Target to $8

HC Wainwright & Co. analyst Robert Burns has maintained a 'Buy' rating on ADC Therapeutics (NYSE: ADCT) and raised the price target from $7 to $8.